基于万古霉素的PET与光学示踪剂在骨科植入物感染模型中的活体细菌靶向成像
研究在C57BL/6小鼠股骨远端不锈钢K-wire植入感染模型中,评估两种新型万古霉素PET示踪剂[¹⁸F]BODIPY-FL-vancomycin、[¹⁸F]VE1-PQ-vancomycin及荧光示踪剂vancomycin-IRDye800CW对生物膜相关骨科植入物感染的诊断价值。结果显示两种PET示踪剂在金黄色葡萄球菌感染腿中摄取显著高于无菌对照,但区分金黄色葡萄球菌与大肠杆菌感染的能力较弱;[¹⁸F]FDG未能区分K-wire感染与无菌对照;vancomycin-IRDye800CW特异性聚集于金黄色葡萄球菌感染部位,而不聚集于大肠杆菌感染或无菌对照。
要点
- 万古霉素PET示踪剂在金黄色葡萄球菌感染中摄取显著高于无菌对照。
- 光学示踪剂可区分革兰阳性与革兰阴性感染,PET示踪剂未能区分。
- 本模型中[¹⁸F]FDG未能区分K-wire感染与无菌对照。
核心结论
- 基于万古霉素的PET与光学示踪剂在小鼠模型中可将细菌感染与无菌K-wire对照区分开。
- 光学成像可区分革兰阳性与革兰阴性细菌感染,而PET示踪剂未能区分。
- 这些临床前发现支持进一步研究万古霉素示踪剂用于假体关节和骨折相关感染的无创成像。
研究设计与样本
- 临床前活体小鼠模型研究,C57BL/6小鼠(n=72)股骨远端植入不锈钢Kirschner(K)-wire。
- 植入物分别接种生物发光金黄色葡萄球菌、大肠杆菌或PBS(无菌对照)。
- 植入感染后第13-14天注射万古霉素示踪剂或[¹⁸F]FDG(基准对照),行PET/CT或荧光成像。
- 量化感染部位示踪剂聚集,并进行生物分布分析和细菌载量评估。
主要发现
- 两种万古霉素PET示踪剂在金黄色葡萄球菌感染腿中的摄取显著高于无菌对照。
- PET示踪剂在金黄色葡萄球菌与大肠杆菌感染之间的结合差异较不明显。
- 本模型中[¹⁸F]FDG未能区分K-wire感染与无菌对照。
- vancomycin-IRDye800CW特异性聚集于金黄色葡萄球菌感染部位,而不聚集于大肠杆菌感染部位或无菌对照。
临床怎么用
- 万古霉素示踪剂有望用于假体关节和骨折相关感染的无创细菌靶向成像。
- 光学示踪剂vancomycin-IRDye800CW可用于区分革兰阳性与革兰阴性感染。
- PET示踪剂在本模型中未能区分革兰阳性与革兰阴性感染,需进一步优化。
局限性
- 结果为临床前小鼠模型数据,尚未在人体中验证。
- PET示踪剂区分金黄色葡萄球菌与大肠杆菌感染的能力较不明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prosthetic joint- and fracture-related infections are major postoperative complications. Early, specific, and preferably non-invasive diagnostic tools, such as bacteria-targeting imaging agents, are essential for optimal treatment, since current approaches, including white blood cell scintigraphy and [¹⁸F]FDG-PET, are accurate, but may lack specificity. Vancomycin, an antibiotic targeting Gram-positive bacteria, has been successfully applied as a molecular scaffold for bacteria-specific tracer development. This study evaluated two novel vancomycin-based PET tracers, [¹⁸F]BODIPY-FL-vancomycin and [¹⁸F]VE1-PQ-vancomycin, along with the fluorescent tracer vancomycin-IRDye800CW, for diagnosing biofilm-associated orthopaedic implant infections. METHODS: We employed a preclinical in vivo model of orthopaedic implant infection, where C57BL/6 mice (n = 72) received stainless-steel Kirschner (K)-wire implants in the distal femur, which were inoculated with bioluminescent Staphylococcus aureus or Escherichia coli bacteria, or with PBS (sterile control). At days 13-14 post-implant infection, animals were injected with one of the vancomycin tracers or [¹⁸F]FDG (benchmark control) and underwent PET/CT or fluorescence imaging. Tracer accumulation at the infection site was quantified, followed by biodistribution analysis and bacterial load assessment. RESULTS: Both vancomycin-based PET tracers showed significantly higher uptake in S. aureus-infected legs compared to sterile controls. The differences in binding between S. aureus or E. coli were less distinct. In this model, [18F]FDG did not distinguish K-wire infection from sterile controls. Vancomycin-IRDye800CW accumulated specifically at S. aureus infection sites, but not at E. coli infection sites or sterile controls, indicating accurate bacteria-targeted imaging. CONCLUSION: Vancomycin-based PET and optical tracers differentiated bacterial infection from the sterile K-wire controls in a murine model. Optical imaging distinguished Gram-positive from Gram-negative bacterial infection, whereas PET tracers did not. These preclinical findings support further investigation of vancomycin-based tracers for non-invasive imaging of prosthetic joint and fracture-related infections.
引用
- Spoelstra GB, Braams LM, IJpma FFA, et al. In vivo bacteria-targeted imaging with vancomycin-based positron emission tomography and optical tracers in an orthopaedic trauma implant infection model. Eur J Nucl Med Mol Imaging. 2026. PMID: 42315638. doi:10.1007/s00259-026-07997-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。